Lnhc patent expiration
1. Sitavig patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791127 | LNHC | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(2 years from now) | |
| US8747896 | LNHC | Mucosal bioadhesive slow release carrier for delivering active principles |
Jun, 2027
(2 years from now) | |
| US8592434 | LNHC | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
Jun, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 12, 2016 |
Drugs and Companies using ACYCLOVIR ingredient
Market Authorisation Date: 12 April, 2013
Treatment: Treatment of herpes labialis
Dosage: TABLET
More Information on Dosage
SITAVIG family patents
2. Zelsuvmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 10 months from now) | |
| US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(6 years from now) | |
| US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(6 years from now) | |
| US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(7 years from now) | |
| US10265334 | LNHC | Anhydrous compositions |
Jul, 2032
(7 years from now) | |
| US9289442 | LNHC | Topical compositions |
Jul, 2032
(7 years from now) | |
| US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(9 years from now) | |
| US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(9 years from now) | |
| US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(10 years from now) | |
| US10736839 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
| US10322081 | LNHC | Topical antiviral compositions and methods of using the same |
Jul, 2035
(10 years from now) | |
| US11040006 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
| US11723858 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: Method of treating skin ailment with nitric oxide releasing macromolecules and hydrophilic gel; Method of application of topical pharmaceutical composition to treat dermatological condition; Method of...
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents